CCL2 and atherosclerosis: In an animal model of cerebrovascular illness, the implant considerably decreased the levels of serum calcineurin, Interleukin-1β (IL-1β), Interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), offering long-lasting relief from atherosclerosis (Figure 11).